The Week in Review: ChinaBio® Investor Forum Showcases Young Companies

The 8th ChinaBio® Investor Forum, held in Shanghai, gave “Most Promising Company” awards to three young China life science companies; Hainan Honz Pharmaceutical Co. staged a $238 Million IPO in Shanghai; Charles River Laboratories defended its $1.6 billion purchase of WuXi PharmaTech (药明康德); Radient Pharma announced new plans to divest its rogue China subsidiary; Hemispherx Biopharma and China CRO Fountain Medical Development will seek SFDA approval of Hemispherx’s flu drug; Dehaier Medical Systems will distribute Heyer Medical’s line of ultrasonic nebulizers; Astellas Pharma of Japan will bulk up its sales force to help double its China sales; and Smith & Nephew opened a new 10,000 square meter manufacturing plant in Beijing this week. More details… Stock Symbols: (GEM: 300086) (NYSE: CRL) (NYSE: WX) (NYSE AMEX: RPC) (AMEX: HEB) (NSDQ: DHRM) (NYSE: SNN)